Last reviewed · How we verify
No oral anticoagulation
At a glance
| Generic name | No oral anticoagulation |
|---|---|
| Sponsor | University Hospital, Strasbourg, France |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation (NA)
- Catheter Ablation Plus LAAO Versus Anticoagulation in Frail Elderly Patients With Atrial Fibrillation (NA)
- PRO-AF 52: Monthly Primary-Care 12-Lead ECG Screening for Incident Atrial Fibrillation in Adults Aged ≥65 Years
- SNAP AF-52: Dose Appropriateness and Adherence to Oral Anticoagulation in Adults ≥65 With Atrial Fibrillation in Primary Care (Ordu, Türkiye)
- A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+ (NA)
- DOAC - Dosing Options in AntiCoagulation Prophylaxis (PHASE3)
- Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress (PHASE4)
- Warfarin Effects on Male Fertility After Cardiac Surgery
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- No oral anticoagulation CI brief — competitive landscape report
- No oral anticoagulation updates RSS · CI watch RSS
- University Hospital, Strasbourg, France portfolio CI